Assuntos
Tuberculose , Idoso , Ásia/epidemiologia , Humanos , Tuberculose/diagnóstico , Tuberculose/epidemiologiaRESUMO
Although cycloserine (CS) is recommended by the World Health Organization as a second-line agent for the treatment of multidrug-resistant tuberculosis (MDR-TB), safety concerns have impeded its uptake by several national TB programmes. Terizidone (TRD), a structural analogue of cycloserine, may be better tolerated. To assess the safety of CS and TRD for TB treatment, a systematic review and meta-analysis were conducted. From articles published up to December 2011, 27 studies with 2164 patients were included in our review of CS use. The pooled estimate for the frequencies of any adverse drug reaction (ADR) from CS was 9.1% (95%CI 6.4-11.7); it was 5.7% (95%CI 3.7-7.6) for psychiatric ADRs, and 1.1% (95%CI 0.2-2.1) for central nervous system (CNS) related ADRs. TRD showed no better to moderately better safety than CS in a systematic review of the available literature. The published evidence suggests that CS is associated with a higher frequency of psychiatric and CNS-related ADRs than other second-line drugs. While data were limited, treatment discontinuation rates appeared to be manageable. There were no significant differences in tolerability by region, study period or combination. As countries review and revise their treatment programmes, CS, and potentially TRD, should be included in MDR-TB treatment regimens. Adequate information on possible ADRs should be provided to patients, their families and attending health care workers. Greater attention to MDR-TB patients' mental health and a significant increase in resources devoted to pharmacovigilance and treatment of MDR-TB are essential.
Assuntos
Ciclosserina/efeitos adversos , Isoxazóis/efeitos adversos , Oxazolidinonas/efeitos adversos , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , Antibióticos Antituberculose/efeitos adversos , Antibióticos Antituberculose/uso terapêutico , Doenças do Sistema Nervoso Central/induzido quimicamente , Doenças do Sistema Nervoso Central/epidemiologia , Ciclosserina/uso terapêutico , Humanos , Isoxazóis/uso terapêutico , Transtornos Mentais/induzido quimicamente , Transtornos Mentais/epidemiologia , Oxazolidinonas/uso terapêuticoRESUMO
The production of guidelines for the management of drug-resistant tuberculosis (TB) fits the mandate of the World Health Organization (WHO) to support countries in the reinforcement of patient care. WHO commissioned external reviews to summarise evidence on priority questions regarding case-finding, treatment regimens for multidrug-resistant TB (MDR-TB), monitoring the response to MDR-TB treatment, and models of care. A multidisciplinary expert panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to develop recommendations. The recommendations support the wider use of rapid drug susceptibility testing for isoniazid and rifampicin or rifampicin alone using molecular techniques. Monitoring by sputum culture is important for early detection of failure during treatment. Regimens lasting ≥ 20 months and containing pyrazinamide, a fluoroquinolone, a second-line injectable drug, ethionamide (or prothionamide), and either cycloserine or p-aminosalicylic acid are recommended. The guidelines promote the early use of antiretroviral agents for TB patients with HIV on second-line drug regimens. Systems that primarily employ ambulatory models of care are recommended over others based mainly on hospitalisation. Scientific and medical associations should promote the recommendations among practitioners and public health decision makers involved in MDR-TB care. Controlled trials are needed to improve the quality of existing evidence, particularly on the optimal composition and duration of MDR-TB treatment regimens.
Assuntos
Tuberculose Resistente a Múltiplos Medicamentos/prevenção & controle , Tuberculose Resistente a Múltiplos Medicamentos/terapia , Assistência Ambulatorial , Antituberculosos/farmacologia , Controle de Doenças Transmissíveis , Tuberculose Extensivamente Resistente a Medicamentos/prevenção & controle , Tuberculose Extensivamente Resistente a Medicamentos/terapia , Guias como Assunto , Humanos , Mycobacterium tuberculosis/metabolismo , Saúde Pública , Escarro , Resultado do Tratamento , Organização Mundial da SaúdeRESUMO
ß-N-methylamino-L-alanine (BMAA) is produced by diverse taxa of cyanobacteria, and has been detected by many investigators who have searched for it in cyanobacterial blooms, cultures and collections. Although BMAA is distinguishable from proteinogenic amino acids and its isomer 2,4-DAB using standard chromatographic and mass spectroscopy techniques routinely used for the analysis of amino acids, we studied whether BMAA could be reliably distinguished from other diamino acids, particularly 2,6-diaminopimelic acid which has been isolated from the cell walls of many bacterial species. We used HPLC-FD, UHPLC-UV, UHPLC-MS, and triple quadrupole tandem mass spectrometry (UHPLC-MS/MS) to differentiate BMAA from the diamino acids 2,6-diaminopimelic acid, N-2(amino)ethylglycine, lysine, ornithine, 2,4-diaminosuccinic acid, homocystine, cystine, tryptophan, as well as other amino acids including asparagine, glutamine, and methionine methylsulfonium.
Assuntos
Diamino Aminoácidos/química , Aminoácidos Dicarboxílicos/química , Cianobactérias/química , Cromatografia Líquida de Alta Pressão/métodos , Ácido Diaminopimélico/química , Espectrometria de MassasRESUMO
Competency at graduation, in a variety of physical and attitudinal skills, is an essential outcome measure for courses training veterinary surgeons. The approach adopted by the Royal Veterinary College, London, to identify and define the expected skill competencies required of our veterinary undergraduates by the time of graduation is described. In addition, we demonstrate how this skill set was built into a framework that was aligned with other student learning objectives. This two-year project resulted in the publication of a day-one skills handbook, which was introduced to the college staff and students in 2007.
Assuntos
Competência Clínica , Currículo/normas , Educação em Veterinária/normas , Medicina Veterinária/normas , Animais , Medicina Baseada em Evidências , Humanos , Aprendizagem Baseada em ProblemasRESUMO
OBJECTIVE: To investigate anti-tuberculosis (TB) drug resistance rates in Donetsk Oblast, Ukraine, and to explore the association between the epidemics of human immunodeficiency virus (HIV) and multidrug-resistant TB (MDR-TB). METHODS: All consecutive newly diagnosed and previously treated patients with sputum smear-positive TB presenting to all TB units in Donetsk Oblast over 12 months were invited to take part in the study. A total of 1293 and 203 patients with TB were tested for HIV and MDR-TB in the civilian and penitentiary sectors, respectively. RESULTS: Of those enrolled for the study, 307 were HIV-positive, 379 had MDR-TB, and 97 had MDR-TB and HIV co-infection. MDR-TB rates in the civilian sector were respectively 15.5% (95%CI 13.1-17.8) and 41.5% (95%CI 36.4-46.5) in newly diagnosed and previously treated TB patients. Among prisoners, MDR-TB rates were 21.8% (95%CI 12.4-31.2) in new cases and 52.8% (95%CI 43.9-61.7) in previously treated TB cases. HIV status was significantly associated with MDR-TB (OR 1.7, 95%CI 1.3-2.3). CONCLUSIONS: High MDR-TB rates and a positive association between MDR-TB and HIV epidemics were found in Donetsk Oblast. Urgent measures to improve HIV prevention, control of drug-resistant TB and collaboration between HIV and TB control activities need to be implemented without further delay.
Assuntos
Surtos de Doenças , Infecções por HIV/epidemiologia , Tuberculose Resistente a Múltiplos Medicamentos/epidemiologia , Adulto , Antituberculosos/uso terapêutico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prisioneiros , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , Ucrânia/epidemiologiaAssuntos
Prestação Integrada de Cuidados de Saúde/normas , Infecções por HIV/terapia , Tuberculose/terapia , Terapia Diretamente Observada , Infecções por HIV/complicações , Infecções por HIV/prevenção & controle , Humanos , Programas de Rastreamento/organização & administração , Tuberculose/complicações , Tuberculose/prevenção & controleRESUMO
Tuberculosis (TB) and human immunodeficiency virus (HIV) programs are increasingly working together towards providing universal access to integrated TB and HIV prevention, treatment, care and support services. To monitor progress we need to measure the delivery and impact of these services; however, the lack of investment in monitoring and evaluation and the added complexity of sharing data between two vertical programs, makes monitoring and evaluation of collaborative TB-HIV activities especially challenging. We describe the global system to record, report and analyse data on collaborative TB-HIV activities and summarize results to date. Although the data suggest that there is a steady increase in collaborative TB-HIV activities in many high-burden countries over time, we are already falling behind the globally agreed implementation milestones. This is due to a combination of slow implementation and lack of necessary tools and systems for capturing activity data. In particular, data from HIV program monitoring of TB screening, TB preventive treatments and TB infection control for people living with HIV is lacking. Much remains to be done by both programs to improve the implementation, monitoring and evaluation of collaborative TB-HIV activities and to optimize prevention, treatment and care for people infected with both TB and HIV, especially in areas at high risk of drug-resistant TB.
Assuntos
Prestação Integrada de Cuidados de Saúde/organização & administração , Infecções por HIV/terapia , Tuberculose/terapia , Coleta de Dados/métodos , Terapia Diretamente Observada/normas , Farmacorresistência Bacteriana , Saúde Global , Infecções por HIV/complicações , Infecções por HIV/prevenção & controle , Humanos , Programas de Rastreamento/organização & administração , Avaliação de Processos e Resultados em Cuidados de Saúde , Tuberculose/complicações , Tuberculose/prevenção & controleRESUMO
BACKGROUND: The human immunodeficiency virus (HIV) is a key factor responsible for the high rates of tuberculosis (TB) in sub-Saharan Africa. Treatment of TB with rifampicin (R, RMP) containing short-course regimens is highly effective in HIV-infected adults. We conducted a study to compare the efficacy and safety of intermittent ethambutol (E, EMB) with two RMP-containing regimens to treat pulmonary TB in HIV-infected patients. SETTING: National Tuberculosis Treatment Centre, Mulago Hospital, Kampala, Uganda. DESIGN: This was a prospective cohort compared to two non-randomised control groups. The study group and the two control arms were treated with 2 months of isoniazid (H), RMP, pyrazinamide (Z) and EMB followed by 6 E3H3 for the study group and 4HR or 6HR for controls. RESULTS: Between April 1993 and March 2000, 136 patients were enrolled in the 2EHRZ/E3H3 arm, 147 in the 2EHRZ/4HR arm and 266 in the 2EHRZ/6HR arm. The relapse rate was 18.2 per 100 person-years observation (PYO) for the study regimen compared to 9.7/100 PYO (P = 0.0063) and 4.8/100 PYO (P = 0.0001) in patients treated with 2 EHRZ/4HR or 2EHRZ/6HR, respectively. CONCLUSION: The 2EHRZ/6E3H3 regimen is safe and effective but has a significant risk of relapse.
Assuntos
Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Antituberculosos/administração & dosagem , Etambutol/administração & dosagem , Rifampina/administração & dosagem , Tuberculose Pulmonar/tratamento farmacológico , Adulto , Esquema de Medicação , Quimioterapia Combinada , Feminino , Humanos , Masculino , Recidiva , Resultado do Tratamento , UgandaRESUMO
The World Health Organization (WHO) has set a target of treating 3 million people with antiretroviral treatment (ART) by 2005. In sub-Saharan Africa, HIV-positive tuberculosis (TB) patients could significantly contribute to this target. ART (stavudine/lamivudine/nevirapine) was initiated in Thyolo district, Malawi, in April 2003, and all HIV-positive TB patients were considered eligible and offered ART. Despite this, only 44 (13%) of 352 TB patients were eventually started on ART by the end of November 2003. Most TB patients leave hospital after 2 weeks to complete the initial phase of anti-tuberculosis treatment (rifampicin-based) in the community, and ART is offered to HIV-positive TB patients after they have started the continuation phase of treatment (isoniazid/ ethambutol). ART is only offered at hospital, while the majority of TB patients take their continuation phase of anti-tuberculosis treatment from health centres. HIV-positive TB patients therefore find it difficult to access ART. In this paper, we discuss a series of options to increase the uptake of ART among HIV-positive TB patients. The main options are: 1) to hospitalise HIV-positive TB patients with a view to starting ART in the continuation phase in hospital; 2) to decentralise ART delivery so ART can be delivered at health centres; 3) to replace nevirapine with efavirenz so ART can be started earlier in the initial phase of anti-tuberculosis treatment. Decentralisation of ART from hospitals to health centres would greatly improve ART access.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Soropositividade para HIV/tratamento farmacológico , População Rural , Tuberculose/tratamento farmacológico , Terapia Antirretroviral de Alta Atividade/métodos , Antituberculosos/uso terapêutico , Quimioterapia Combinada , Uso de Medicamentos , Soropositividade para HIV/complicações , Soropositividade para HIV/epidemiologia , Humanos , Lamivudina/uso terapêutico , Malaui/epidemiologia , Programas Nacionais de Saúde/tendências , Nevirapina/uso terapêutico , Prevalência , Estavudina/uso terapêutico , Tuberculose/complicações , Tuberculose/epidemiologia , Organização Mundial da SaúdeRESUMO
SETTING: Thyolo district, Malawi. OBJECTIVES: To determine in HIV-positive individuals aged over 13 years CD4 lymphocyte counts in patients classified as WHO Clinical Stage III and IV and patients with active and previous tuberculosis (TB). DESIGN: Cross-sectional study. METHODS: CD4 lymphocyte counts were determined in all consecutive HIV-positive individuals presenting to the antiretroviral clinic in WHO Stage III and IV. RESULTS: A CD4 lymphocyte count of < or = 350 cells/microl was found in 413 (90%) of 457 individuals in WHO Stage III and IV, 96% of 77 individuals with active TB, 92% of 65 individuals with a history of pulmonary TB (PTB) in the last year, 91% of 89 individuals with a previous history of PTB beyond 1 year, 81% of 32 individuals with a previous history of extra-pulmonary TB, 93% of 107 individuals with active or past TB with another HIV-related disease and 89% of 158 individuals with active or past TB without another HIV-related disease. CONCLUSIONS: In our setting, nine of 10 HIV-positive individuals presenting in WHO Stage III and IV and with active or previous TB have CD4 counts of < or = 350 cells/microl. It would thus be reasonable, in this or similar settings where CD4 counts are unavailable for clinical management, for all such patients to be considered eligible for antiretroviral therapy.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Linfócitos T CD4-Positivos/imunologia , Definição da Elegibilidade/métodos , Infecções por HIV/imunologia , Tuberculose/imunologia , Adolescente , Adulto , Contagem de Linfócito CD4 , Estudos Transversais , Feminino , Anticorpos Anti-HIV/imunologia , Infecções por HIV/classificação , Infecções por HIV/tratamento farmacológico , HIV-1/imunologia , HIV-2/imunologia , Humanos , Malaui , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Índice de Gravidade de Doença , Tuberculose/tratamento farmacológico , Organização Mundial da SaúdeRESUMO
SETTING: National Tuberculosis (TB) Control Programme (NTP), Malawi. OBJECTIVES: To determine the feasibility and effectiveness of performance-related allowances for NTP personnel working at central and regional levels in Malawi. In particular, to determine 1) whether programme staff can complete 6-monthly self-assessment forms related to the tasks they are expected to perform during that period, and 2) whether the NTP can achieve four key programme targets related to case finding, treatment outcome and the sending of sputum specimens for drug resistance monitoring. DESIGN: A descriptive study. RESULTS: For January to June 2003, 25 personnel completed self-assessment forms, and in all cases individual performance was judged satisfactory. For July to December 2003, 21 personnel completed self-assessment forms, and in 20 cases individual performance was judged satisfactory. In the first quarter of 2003, only one target was achieved for the country, and NTP personnel were awarded one quarter of the performance payment. In the third quarter, two targets were achieved and NTP personnel were awarded one half of the performance payment. CONCLUSION: It is feasible to implement performance-related payments for NTP personnel. Ways to routinely introduce such a system for NTP and other staff in the health sector urgently need to be explored.
Assuntos
Promoção da Saúde , Salários e Benefícios/economia , Tuberculose/prevenção & controle , Resistência Microbiana a Medicamentos , Humanos , Malaui , Autoavaliação (Psicologia) , Escarro , Resultado do Tratamento , Recursos HumanosRESUMO
SETTING: Zomba Central Hospital, Malawi. OBJECTIVES: To determine the outcome of all adult patients who were registered for tuberculosis (TB) treatment 7 years previously according to initial human immunodeficiency virus (HIV) status and type of TB. DESIGN: A retrospective cohort study of adult patients registered for TB treatment between July and December 1995. Follow-up at patients' homes was performed at the end of treatment, at 32 months and at 84 months (7 years) from the time of TB registration. FINDINGS: Eight hundred and twenty-seven TB patients were registered: 793 had concordant HIV test results, of whom 612 (77%) were HIV-positive. At 7 years, 136 (17%) patients were alive, 539 (65%) had died and 152 (18%) were lost to follow-up. The death rate for all TB patients was 23.7 per 100 person-years of observation. HIV-positive patients had higher death rates than HIV-negative patients (hazard ratio [HR] 2.2, 95% confidence interval [95%CI] 1.7-2.8). Death rates in smear-negative pulmonary TB patients (HR 2.1, 95%CI 1.7-2.6) and in patients with extra-pulmonary TB (HR 1.7, 95% CI 1.3-2.0) were higher than in patients with smear-positive PTB. CONCLUSIONS: There was a high mortality rate in TB patients during and after anti-tuberculosis treatment. Adjunctive treatments to reduce death rates are urgently needed.
Assuntos
Infecções por HIV/complicações , Tuberculose Pulmonar/mortalidade , Tuberculose Pulmonar/virologia , Adulto , Antituberculosos/uso terapêutico , Feminino , Seguimentos , Humanos , Malaui , Masculino , Pessoa de Meia-Idade , Escarro/citologia , Análise de Sobrevida , Resultado do Tratamento , Tuberculose Pulmonar/tratamento farmacológicoRESUMO
Tuberculosis (TB) still imposes a huge burden of ill health, premature death and emotional suffering on the developing world. Over the past 30 y it has been greatly neglected by those concerned about international public health and there are now nearly 8 million new cases annually and 1.86 million deaths. An epidemic of HIV-associated TB is now affecting Africa and threatening parts of Asia. Multidrug-resistant TB has emerged as a huge threat in Russia and its former satellites. However, with the advent of the directly observed treatment, short-course (DOTS) strategy in 1995, high-burden countries have started to seriously address the problem. Recent political commitment on the part of the rich nations, together with significant increases in funding from private foundations and great scientific advances in our understanding of Mycobacterium tuberculosis, give rise to cautious optimism that TB will be controlled during this century.
Assuntos
Infecções Oportunistas Relacionadas com a AIDS/prevenção & controle , Países em Desenvolvimento , Tuberculose/prevenção & controle , Organização Mundial da Saúde , Infecções Oportunistas Relacionadas com a AIDS/epidemiologia , Humanos , Política , Setor Privado , Tuberculose/epidemiologia , Organização Mundial da Saúde/organização & administraçãoAssuntos
Antituberculosos , Pesquisa/organização & administração , Tuberculose/tratamento farmacológico , Tuberculose/prevenção & controle , Controle de Doenças Transmissíveis/organização & administração , Saúde Global , Humanos , Relações Interinstitucionais , Cooperação Internacional , Apoio à Pesquisa como Assunto , Tuberculose/epidemiologia , Tuberculose Resistente a Múltiplos MedicamentosAssuntos
Saúde Global , Tuberculose/epidemiologia , Tuberculose/prevenção & controle , Controle de Doenças Transmissíveis/métodos , Efeitos Psicossociais da Doença , Países Desenvolvidos , Países em Desenvolvimento , Previsões , Prioridades em Saúde , Humanos , Avaliação das Necessidades , Vigilância da População/métodos , Fatores de Risco , Tuberculose/transmissão , Organização Mundial da SaúdeAssuntos
Controle de Doenças Transmissíveis/organização & administração , Controle de Doenças Transmissíveis/tendências , Hanseníase/epidemiologia , Hanseníase/prevenção & controle , Medicina Tropical/organização & administração , Previsões , Educação em Saúde/organização & administração , Humanos , Desenvolvimento de Programas , Pesquisa/organização & administraçãoRESUMO
SETTING: Queen Elizabeth Central Hospital, Blantyre, and Zomba Central Hospital, Zomba, Malawi. OBJECTIVE: To follow-up human immunodeficiency virus (HIV) seropositive and HIV-seronegative patients with smear-negative pulmonary tuberculosis (PTB) and pleural TB who had completed treatment with two different regimens in Blantyre and Zomba, and to assess rates of mortality and recurrent TB. DESIGN: Patients with smear-negative and pleural TB who had completed 8 months ambulatory treatment in Blantyre or 12 months standard treatment in Zomba and who were smear and culture negative for acid-fast bacilli at the completion of treatment were actively followed every 4 months for a total of 20 months. RESULTS: Of 248 patients, 150 with smear-negative PTB and 98 with pleural TB, who completed treatment and were enrolled, 205 (83%) were HIV-positive. At 20 months, 145 (58%) patients were alive, 85 (34%) had died and 18 (7%) had transferred out of the district. The mortality rate was 25.7 per 100 person-years, with increased rates strongly associated with HIV infection and age >45 years. Forty-nine patients developed recurrent TB. The recurrence rate of TB was 16.1 per 100 person-years, with increased rates strongly associated with HIV infection, having smear-negative PTB and having received 'standard treatment'. CONCLUSION: High rates of mortality and recurrent TB were found in patients with smear-negative PTB and pleural effusion during 20 months of follow-up. TB programmes in sub-Saharan Africa must consider appropriate interventions, such as co-trimoxazole and secondary isoniazid prophylaxis, to reduce these adverse outcomes.